">
Friday, 20 March 2026
  
Login

Australia's most trusted
source of pharma news

Friday, 20 March 2026
News

CEO's $29 million Swan Song

Posted 20 March 2026 PM

GSK's former CEO Emma Walmsley bowed out on a high when she finished up with the company in December, with a total compensation package that soared nearly 50 per cent in 2025 to AU$29.5 million.

After nine years at the top, Walmsley stepped down from both the CEO role and her Board position, handing the baton to former Chief Commercial Officer, Australian Luke Miels from New Years Day.

To see the whole article, please login

Popular

Novo slapped with Warning Letter
'Bad juju' crashes Aussie company
World's top drug, by a loophole
A-list attends Sanofi office opening
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home